Authors: Sharon Salt, Editor
A team of scientists led by Manuel Valiente, head of the Brain Metastasis Group at the Spanish National Cancer Research Center (CNIO; Madrid, Spain), have demonstrated that the administration of silibinin in patients with brain metastases reduces lesions without causing any adverse effects.
In 2016, the anti-tumor potential of silibinin was established where researchers reported positive brain responses in two patients with no other treatment options. At the time, the researchers didn’t understand how silibinin worked. However, in the current study, the researchers believe that they have now revealed how it acts at the level of the brain. The preliminary trial results have been published in Nature Medicine.